TY - JOUR
T1 - Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation
AU - Christodoulides, Nicolaos J.
AU - McRae, Michael P.
AU - Abram, Timothy J.
AU - Simmons, Glennon W.
AU - McDevitt, John T.
N1 - Funding Information:
The p-BNC technology and methods were developed and validated in six major clinical studies funded by the National Institute of Dental and Craniofacial Research division of the National Institutes of Health, the Cancer Prevention Research Institute of Texas, and the United Kingdom’s Home Office Centre of Applied Science and Technology. These studies yielded innovations in application areas, including cardiac wellness, oral cancer screening, and drugs of abuse testing. These programs are described below.
Funding Information:
This work was supported in part by the National Institutes of Health (NIH) through the National Institute of Dental and Craniofacial Research (award numbers 5U01 DE017793 and 5RC2DE020785), the Cancer Prevention Research Institute of Texas (award number RP101382), and the United Kingdom’s Home Office Centre for Applied Science and Technology (CAST) (Grant Number 7165721). The content of this article is solely the responsibility of the authors and does not necessarily represent or reflect the official views of the NIH or the government and other sponsors.
Funding Information:
This work was supported in part by the National Institutes of Health (NIH) through the National Institute of Dental and Craniofacial Research (award numbers 5U01 DE017793 and 5RC2DE020785), the Cancer Prevention Research Institute of Texas (award number RP101382), and the United Kingdom?s Home Office Centre for Applied Science and Technology (CAST)(Grant Number 7165721). The content of this article is solely the responsibility of the authors and does not necessarily represent or reflect the official views of the NIH or the government and other sponsors.
Publisher Copyright:
© Copyright © 2017 Christodoulides, McRae, Abram, Simmons and McDevitt.
PY - 2017/5/22
Y1 - 2017/5/22
N2 - The lack of standard tools and methodologies and the absence of a streamlined multimarker approval process have hindered the translation rate of new biomarkers into clinical practice for a variety of diseases afflicting humankind. Advanced novel technologies with superior analytical performance and reduced reagent costs, like the programmable bio-nano-chip system featured in this article, have potential to change the delivery of healthcare. This universal platform system has the capacity to digitize biology, resulting in a sensor modality with a capacity to learn. With well-planned device design, development, and distribution plans, there is an opportunity to translate benchtop discoveries in the genomics, proteomics, metabolomics, and glycomics fields by transforming the information content of key biomarkers into actionable signatures that can empower physicians and patients for a better management of healthcare. While the process is complicated and will take some time, showcased here are three application areas for this flexible platform that combines biomarker content with minimally invasive or non-invasive sampling, such as brush biopsy for oral cancer risk assessment; serum, plasma, and small volumes of blood for the assessment of cardiac risk and wellness; and oral fluid sampling for drugs of abuse testing at the point of need.
AB - The lack of standard tools and methodologies and the absence of a streamlined multimarker approval process have hindered the translation rate of new biomarkers into clinical practice for a variety of diseases afflicting humankind. Advanced novel technologies with superior analytical performance and reduced reagent costs, like the programmable bio-nano-chip system featured in this article, have potential to change the delivery of healthcare. This universal platform system has the capacity to digitize biology, resulting in a sensor modality with a capacity to learn. With well-planned device design, development, and distribution plans, there is an opportunity to translate benchtop discoveries in the genomics, proteomics, metabolomics, and glycomics fields by transforming the information content of key biomarkers into actionable signatures that can empower physicians and patients for a better management of healthcare. While the process is complicated and will take some time, showcased here are three application areas for this flexible platform that combines biomarker content with minimally invasive or non-invasive sampling, such as brush biopsy for oral cancer risk assessment; serum, plasma, and small volumes of blood for the assessment of cardiac risk and wellness; and oral fluid sampling for drugs of abuse testing at the point of need.
KW - biomarkers
KW - in vitro diagnostics
KW - medical microdevices
KW - non-invasive sampling
KW - point of care
UR - http://www.scopus.com/inward/record.url?scp=85053414156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053414156&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2017.00110
DO - 10.3389/fpubh.2017.00110
M3 - Review article
AN - SCOPUS:85053414156
SN - 2296-2565
VL - 5
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 110
ER -